Related Experiment Video
Updated: Jan 19, 2026

06:23
Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
8.5K
Dendrobium alkaloids decrease Aβ by regulating α- and β-secretases in hippocampal neurons of SD rats
Juan Huang1, Nanqu Huang2, Minghui Zhang3
1Key Laboratory of Basic Pharmacology and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China.
Peerj
|September 20, 2019
Summary
Dendrobium nobile Lindl. alkaloids (DNLA) reduce amyloid beta (Aβ) production in rat hippocampal neurons by regulating secretase enzymes. This suggests DNLA may offer therapeutic benefits for Alzheimer's disease.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Alzheimer's disease (AD) is a leading cause of dementia, characterized by amyloid-beta (Aβ) imbalance.
- Dendrobium nobile Lindl. alkaloids (DNLA) show anti-aging and neuroprotective effects, improving memory in mice.
- The precise mechanism of DNLA's neuroprotective action, particularly concerning Aβ, remains unclear.
Purpose of the Study:
- To investigate the effect of DNLA on amyloid-beta (Aβ) production in hippocampal neurons.
- To elucidate the underlying molecular mechanisms of DNLA's potential therapeutic benefits for Alzheimer's disease.
Main Methods:
- Cultured rat hippocampal neurons were treated with DNLA.
- Cell viability was assessed using MTT assays.
- Protein expression levels of key molecules (APP, ADAM10, BACE1, ADAM17, Aβ) were analyzed via Western blot.
Main Results:
- DNLA treatment did not significantly alter hippocampal neuron viability.
- DNLA reduced the protein expression of amyloid precursor protein (APP), ADAM10, BACE1, and Aβ₁₋₄₂.
- DNLA increased the protein expression of ADAM17.
Conclusions:
- DNLA effectively decreases amyloid-beta (Aβ) levels in rat hippocampal neurons.
- DNLA achieves this by modulating the activity of α-secretase and β-secretase pathways.
- These findings highlight DNLA's potential as a therapeutic agent for Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Treatment
831
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
831
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K

